InvestorsHub Logo
Followers 3
Posts 190
Boards Moderated 0
Alias Born 05/16/2013

Re: None

Monday, 03/07/2016 11:35:47 AM

Monday, March 07, 2016 11:35:47 AM

Post# of 426549
Any chance the 1A negotiations will allow AMRN to promote for other, non-CVD indications? We've been soaking up the news about EPA's potential benefits for diabetes, depression, dry eye syndrome (just to mention the D's). If the 1A settlement is about "truthful and non-misleading" speech/advertising, couldn't it possibly be put in service of other off-label uses? I'm wondering how others on this board feel about that aspect of the negotiations currently underway. I expect certain people who know FDA, Pharma and medical practices much better than I may be skeptics, but I'm wondering why Amarin wouldn't be pursuing language that would allow them more leeway in these areas, as well.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News